The p53 tumor suppressor protein, a key regulator of cell apoptosis, has been described to accumulate in affected brain areas from Alzheimer's disease (AD) patients. However, whether p53 plays any role in AD pathogenesis remains unknown. Here, we found that exposure of neurons to oligomers of the amyloidogenic fragment 25-35 of the Aß peptide (Aβ 25-35 ) activated Cdk5, which promoted p53 protein phosphorylation and stabilization. Moreover, Aβ 25-35 -mediated mitochondrial dysfunction and neuronal apoptosis were prevented by both genetic and pharmacological inhibition of either p53 or Cdk5 activities. To confirm this mechanism in vivo, Aβ 25-35 was stereotaxically injected in the cerebral right ventricle of mice, a treatment that caused p53 protein accumulation, dendrite disruption and neuronal death. Furthermore, these effects were prevented in p53 knockout mice or by pharmacologically inhibiting p53. Thus, Aβ 25-35 triggers Cdk5 activation to induce p53 phosphorylation and stabilization, which leads to neuronal damage. Inhibition of the Cdk5-p53 pathway may therefore represent a novel therapeutic strategy against Aβ-induced neurodegeneration. Contributors Rebeca Lapresa, Irene Sánchez-Morán, and Jesus Agulla performed the in vitro experiments and analyzed biochemical data. Rebeca Lapresa and Jesus Agulla performed the in vivo experiments. Juan P Bolaños analyzed data and contributed to design the in vitro experiments.
Introduction
Alzheimer's Disease (AD) is a complex multifactorial neurodegenerative disease (Selkoe and Hardy, 2016) and the most common form of dementia in the elderly (Winblad et al., 2016) .
The progressive degeneration of neurons in selective brain regions involved in learning and memory, primarily hippocampus and cortex, results in gradual decline of cognitive function (Selkoe and Hardy, 2016) . The main neuropathological hallmarks of AD are the accumulation of abnormally folded amyloid-β (Aβ) peptide and truncated and hyperphosphorylated tau proteins in senile plaques and neuronal tangles, which are causally related to the progression of the neurodegenerative process . According to the widely accepted amyloid cascade hypothesis, the accumulation of Aβ in the brain -derived from the proteolytic processing of the amyloid precursor protein-is a primary triggering factor of AD pathogenesis as it initiates a molecular cascade of effects leading to neurodegeneration and the subsequent clinical manifestations of dementia (Karran et al., 2011; Selkoe and Hardy, 2016; Winblad et al., 2016) . Aβ oligomers appear to be the most neurotoxic species, triggering signaling pathways that involve synaptic dysfunction, Ca 2+ homeostasis disruption, oxidative stress, and mitochondrial dysfunction, among others, which culminates in neuronal apoptosis (Green and LaFerla, 2008; Haass and Selkoe, 2007; Jarosz-Griffiths et al., 2016) .
However, the full underlying mechanism of neuronal apoptosis in response to Aβ is still unknown.
The tumor suppressor protein p53 is a key modulator of cellular responses to genome stress and DNA damage, and p53 activation triggers apoptosis in different cell types, including neurons (Culmsee and Mattson, 2005) . Furthermore, numerous evidences demonstrate an increase in p53 level and activity in degenerating neurons, which appears to be a common feature of neurodegenerative diseases (Culmsee and Mattson, 2005; Szybińska and Leśniak, 2017) . In particular, enhanced p53 level was detected in brain areas undergoing degeneration of AD patients (Hooper et al., 2007; Kitamura et al., 1997) and transgenic animal models of AD (Ohyagi et al., 2005; Szybińska and Leśniak, 2017) . Interestingly, p53 expression increases in parallel with intracellular accumulation of Aβ in some degenerating neurons (Ohyagi et al., 2005) . However, it is still a matter of debate whether increased levels of p53 in neurons of AD brains are really implicated in neuronal death or whether they are consequence of the adaptive responses of neurons until apoptosis occurs (Merlo et al., 2014; Sajan et al., 2007; Szybińska and Leśniak, 2017; Zhang et al., 2002) . Therefore, the nature of the link between p53 and AD remains controversial.
Here we study the function of p53 in Aβ neurotoxicity and the underlying mechanism, trying to identify possible therapeutic targets for AD. We found that oligomers of the neurotoxic fragment 25-35 of the Aß peptide (Aβ 25-35 ) (Pike et al., 1995) promoted Cdk5-induced p53 phosphorylation and functional stabilization, both in primary cultured neurons and in vivo, leading to mitochondrial disfunction and neuronal apoptosis. Moreover, we reveal that p53 modulates neuronal susceptibility to Aβ toxicity and determines brain damage, as genetic or pharmacological (PFTα) inhibition of p53 activity confers resistance to Aß-induced dendrite disruption and neurodegeneration. Hence, the Cdk5-p53 signaling pathway may be the link that couples Aβ with neuronal apoptosis, providing novel therapeutic targets for AD therapy.
Results

Amyloid-ß induces p53 stabilization leading to neuronal apoptosis in vitro
To study the molecular mechanism responsible for Aß oligomer-induced neurotoxicity, primary cortical neurons were first exposed to increasing concentrations of the amyloidogenic fragment 25-35 of the Aß peptide (Aβ 25-35 ) for 24 h and neuronal apoptosis was measured by flow cytometry. As shown in Fig. 1A , oligomerized Aβ 25-35 induced neuronal apoptosis in a concentration-dependent manner, reaching the maximum effect at a concentration of 10 µM, 5 which was selected for further experiments. The time-course study revealed that 10 µM Aβ 25-35 caused both neuronal apoptosis ( Fig. 1B ) and mitochondrial membrane potential (∆ m ) depolarization ( Fig. 1B) . Interestingly, the ∆ m loss preceded apoptotic death upon the Aβ 25-35 exposure, indicating that mitochondrial dysfunction is cause -not consequence-of the neuronal apoptotic process, thus confirming the importance for ∆ m maintenance in neuronal survival (Almeida and Bolaños, 2001; Veas-Pérez de Tudela et al., 2015; White and Reynolds, 1996) .
Given the well-known function of p53 in regulating mitochondrial function and neuronal apoptosis (Culmsee and Mattson, 2005; Gomez-Sanchez et al., 2011; Rodríguez et al., 2016) , we next examined the contribution of p53 to Aβ 25-35 -induced neurotoxicity. We observed an accumulation of p53 protein in neurons from 4 h of Aβ 25-35 exposure (Fig. 1E ). However, no increase was observed in p53 mRNA levels ( Fig. 1D ), revealing that Aβ 25-35 -evoked p53 protein accumulation is because of a post-translational event of p53. Under cellular stress conditions, p53 protein levels raises immediately because of its stabilization by phosphorylation (Lee et al., 2007) . Accordingly, we found that Aβ 25-35 promoted p53 phosphorylation at Ser15 residue, which correlated with the timing of p53 protein accumulation ( Fig. 1E ). Aβ 25-35 -induced accumulation of p53 was functional as revealed by the increase in protein expression of p53 target PUMA, which plays a key role in mitochondrial-mediated apoptosis (Culmsee and Mattson, 2005) . Accordingly, Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] promoted the activation of caspase-3 at 16 h of exposure ( Fig. 1E ), which correlates with the profile of apoptosis induced by Aβ (Fig. 1B) . The functional accumulation of p53 was confirmed by the induction of p53 target genes p21 and PUMA ( Fig. 1F ).
Next, we analyzed the contribution of p53 accumulation to Aβ 25-35 -induced mitochondrial depolarization and neuronal apoptosis by depleting p53 neuronal levels using both small interfering RNA knockdown (sip53) ( Fig. EV1A ) and gene knockout of p53 (p53 -/-).
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Following 24 h of Aβ 25-35 exposure, the lack of p53 accumulation in sip53 ( Fig. EV1A ) and p53 -/- (Fig. 2B ) neurons, which prevented the induction of p53 protein targets, p21 and Bax ( Fig. 2B ), significantly protected against neuronal apoptosis ( Fig. 2A and 2C ) and caspase-3 activation ( Fig. 2B ). Moreover, p53 loss prevented Aβ 25-35 -induced mitochondrial depolarization in neurons ( Fig. 2D ). Finally, the p53-dependent Aβ 25-35 neurotoxicity was confirmed by pharmacological inhibition of p53 transcriptional activity with PFTα, which decreased Aβ 25-35 -induced neuronal apoptosis in a concentration-dependent manner ( Fig. 2E ).
Furthermore, neuronal protection exerted by PFTα was specific and dependent on p53 activity, as the same effect was observed in p53 +/+ and p53 -/neurons ( Fig. 2F ). Altogether, these results demonstrate that Aβ 25-35 promoted p53 phosphorylation and stabilization, which induced the expression of proapoptotic proteins, PUMA and Bax, leading to mitochondrial dysfunction and neuronal apoptosis.
Amyloid-ß-induced p53 phosphorylation was mediated by Cdk5 activation
Once demonstrated that Aβ-induced neurotoxicity is dependent on p53 phosphorylation and stabilization, we aimed to identify the kinase involved in the process. It was described that Cdk5, a proline-directed serine/threonine kinase that plays a key role in neuronal degeneration (Maestre et al., 2008; Patrick et al., 1999) , phosphorylates p53 on Ser15 under stress conditions, leading to its accumulation (Lee et al., 2007) . Cdk5 is persistently activated when bound to its activator p25 (Lee et al., 2000) , generated from the Ca 2+ -dependent proteolytic cleavage of p35 (Kusakawa et al., 2000) , that accumulates in the brain of AD patients with Alzheimer's disease (Patrick et al., 1999) . As shown in Fig. 3A , Aβ 25-35 induced the rapid (within 2 h) accumulation of p25. Moreover, Cdk5 activity, as determined by histone H1 phosphorylation, was increased in neuronal extracts exposed to Aβ 25-35 from 2 h ( Fig. 3B ), then confirming that Aβ 25-35 triggered Cdk5 activation in neurons. Next, we measured 7 intracellular free Ca 2+ concentrations as it promotes calpain activation and consequently p25 formation from p35 (Kusakawa et al., 2000) . Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced the rise in Ca 2+ concentrations in neurons from p53 +/+ , p53 +/and p53 -/mice ( Fig. 3C ). In all cases, this effect was prevented by the N-methyl-d-aspartate (NMDA) receptor inhibitor, MK801, indicating that intracellular Ca 2+ influx was mediated by NMDA receptor stimulation. Moreover, Aβ 25-35 elicited a similar decrease in p35 protein abundance and the accumulation of p25 in both p53 +/+ and p53 +/neurons ( Fig. 3D ), indicating that Aβ 25-35 -triggered Cdk5 activation was independent on p53 levels.
Next, we examined whether Cdk5 activation was responsible for the stabilization of p53 upon Fig. 3I ). Interestingly, we found that p53 accumulated in degenerating neurons, as shown by the co-localization of p53 and active caspase-3 expression, which was prevented by roscovitine treatment (Fig. 3J ). These results support the notion that p53 is phosphorylated by Cdk5 upon Aβ 25-35 exposure, leading to p53 stabilization and the induction of pro-apoptotic protein expression, Bax and PUMA, which promoted mitochondrial depolarization and neuronal death.
Amyloid-ß induces p53 stabilization leading to neuronal apoptosis in vivo
To demonstrate the physiological relevance of our in vitro results, we next aimed to confirm the implication of p53 on Aß neurotoxicity in vivo. First, we evaluated the stabilization of p53 in the hippocampal and cortical regions, as they are early targets in AD (Selkoe and Hardy, 2016) , of the mouse brain after intracerebroventricular injection of oligomerized Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . We 
Discussion
Here, we describe a novel signaling pathway responsible for Aβ 25-35 -induced Cdk5 activation leading to p53 phosphorylation and stabilization, eventually causing mitochondrial 9 dysfunction and neuronal apoptosis. Furthermore, we show that this mechanism operates in vivo as either genetic or pharmacological ablation of p53 activity confers resistance against Aß-induced neuronal dendrite disruption and neurodegeneration. This Cdk5-p53 signaling pathway may thus be a causal link coupling Aβ with neuronal apoptosis.
Mechanistically, it is known that activation of p53 requires a post-translational modification that leads to the stabilization of the protein, which in turn inhibits MDM2-mediated p53 ubiquitination and proteasomal degradation (Lee et al., 2007) . In good agreement with this, we found that Aβ treatment caused p53 phosphorylation and stabilization that induced the expression of mitochondrial proapoptotic proteins PUMA and Bax, and may also directly interacts with mitochondria (Gomez-Sanchez et al., 2011; Green and Kroemer, 2009 ), causing mitochondrial damage and neurodegeneration. Furthermore, was found that p53 was accumulated in the degenerating neurons, and that loss of p53, or p53 inhibition with PFTα, protected these cells against Aß toxicity by preventing the induction of Bax and PUMA, mitochondrial dysfunction and caspase activation. Altogether, these results strongly suggest that p53 accumulation in the brain of AD patients (Hooper et al., 2007; Kitamura et al., 1997) may play a key role on neurodegeneration.
Our data also provides novel insights on the molecular mechanisms of the Cdk5 and p53 interplay. Thus, it is known that Cdk5 binds p53 to induce its phosphorylation, which attenuates MDM2-mediated p53 ubiquitylation, thus inducing nuclear localization and accumulation of the protein (Lee et al., 2007) . In addition, p25-induced Cdk5 hyperactivation (Lee et al., 2000; Liu et al., 2015) is known to take place in several neurological disorders including AD, and this has been associated with alterations in neuronal cytoskeleton, synaptic loss and, ultimately, neurodegeneration (Hisanaga and Endo, 2010; Shah and Rossie, 2018) .
Finally, our previous results showed that NMDA receptor over-stimulation in cortical neurons cause p25-mediated Cdk5 hyperactivation (Maestre et al., 2008) . Now, we found that Aβ increases NMDA receptor-mediated intracellular Ca 2+ levels, leading to p25 formation (by p35 cleaving), which in turn triggers Cdk5 activation. Notably, our data also show that p53 stabilization upon Aß treatment is a consequence of the formation of the p25/Cdk5 complex.
Intriguingly, elevated levels of both p25 (Patrick et al., 1999; Tseng et al., 2002) and p53 (Hooper et al., 2007; Kitamura et al., 1997) have been detected in the cerebral areas undergoing degeneration in AD patients, hence suggesting a potential link between Cdk5/p25 and p53 accumulation and AD. Altogether, these results strongly suggest that the mechanism underlying neuronal apoptosis caused by Aß may occur, at least in part, as a result of a Cdk5mediated p53 stabilization process that leads to the transcriptional activation of mitochondrial-derived proapoptotic proteins.
It has been suggested that the pharmacological prevention of p53-dependent apoptotic cascade activation may represent a novel neuroprotective strategy against sudden injury or chronic disease (Esposito and Cuzzocrea, 2010) . In fact, treatment with the p53 inhibitor, PFTα, has been shown to reduce neuronal death after traumatic brain injury (Plesnila et al., 2007) and to improve the functional recovery following cerebral ischemia (Luo et al., 2009 ).
Interestingly, PFTα has been shown to reduce kainate-induce excitotoxic death and to prevent mitochondrial and dendrite damage (Neema et al., 2005) . In good agreement with these observations, we show that PFTα treatment prevents dendrite disruption and the subsequent neuronal death that follows the intracerebroventricular injection of Aß in mice. Dendrite degeneration and mitochondrial dysfunction are both early pathological events in AD and correlate with cognitive and memory deficits (Cai and Tammineni, 2017) . Indeed, mitochondrial energy generation is essential to supporting synaptic function and dendrite integrity (Cai and Tammineni, 2017) . Therefore, our data supports the notion that PFTα treatment is a promising novel therapeutic strategy against AD by protecting mitochondrial function and dendrite integrity.
In summary, here we show that Aß-induced Cdk5 activation triggers p53 phosphorylation and stabilization, leading to mitochondrial depolarization, dendrite disruption and neuronal death.
This suggests that p53 is an attractive therapeutic target for AD treatment and that the p53 inhibitor, PFTα, may represent a possible therapeutic tool to delaying neurodegeneration in AD patients.
Materials and Methods
Primary neuronal culture
Neuronal cultures were prepared from C57BL/6J and p53 null (p53 -/-, B6.129S2, The Jackson Laboratories, Sacramento, CA, USA) mouse embryo (E14.5) cortices. Animals were maintained in specific-pathogen free facilities at the University of Salamanca, in accordance with Spanish legislation (RD53/2013) under license from the Spanish government and the European Union (2010/63/EU). Protocols were approved by the Bioethics Committee of the Institute of Biomedical Research of Salamanca. All efforts were made to minimize the numbers of animals used. Neurons were seeded at 1.8 x 10 5 cells/cm 2 in Neurobasal medium (Invitrogen, Madrid, Spain) supplemented with 2% B27 (Invitrogen) and 2 mM glutamine (Invitrogen), and incubated at 37ºC in a humidified 5% CO 2 -containing atmosphere. Half of the culture medium was replaced with fresh medium every 3 days. Neurons were used for the experiments on day 9-10 in vitro (Delgado-Esteban et al., 2013) .
Neuronal transfections and treatments
To obtain specific protein knockdown, we used the following small interference RNA (siRNAs; only the forward strand shown): Cdk5, 5´-AAGCCGUACCCGAUGUAUC-3´ (corresponding to nucleotides 859-877) (Veas-Pérez De Tudela et al., 2015); p53, 5´-CCACUUGAUGGAGAGUAUU-3´ (corresponding to nucleotides 955-973) (Delgado- Esteban et al., 2013) . In all cases, a siRNA against luciferase (5'-CUGACGCGGAAUACUUCGAUU-3') was used as control siRNA (siControl). Annealed siRNAs were purchased from Dharmacon (Abgene, Thermo Fisher, Epsom, U.K.). Neurons were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen), following the manufacturer's instructions, and used after 24 (sip53) and 48 (siCdk5) hours. According to the degree of protein knockdown shown in the Supplementary Fig. EV1 , the efficiency of transfection of siRNAs is estimated to be 80-85%.
The active truncated amyloid-β peptide Aβ 25-35 (BioNova Cientifica S.L., Madrid, Spain), was dissolved in distilled water at a concentration of 1 mg/mL and then incubated at 37 °C for 3 days to induce its oligomerization (Almeida et al., 2005) . Neurons were incubated in culture medium containing oligomerized Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (1-25 µM), during the time periods indicated in the 
Flow cytometric detection of apoptotic cell death and mitochondrial membrane potential (Δψ m )
Neurons were carefully detached from the plates using 1 mM EDTA tetrasodium salt in PBS (pH 7.4) at room temperature and neuronal apoptosis and mitochondrial membrane potential (Δψ m ) was assessed by flow cytometry. Neurons were stained with annexin V-allophycocyanin (APC; Becton Dickinson Biosciences, New Jersey, USA) and 7aminoactinomycin D (7-AAD; Becton Dickinson Biosciences) in binding buffer (100 mM HEPES, 140 mM NaCl, 2.5 mM CaCl 2 ) to quantitatively determine the percentage of apoptotic neurons by flow cytometry. The annexin V-APC-stained neurons that were 7-AADnegative were considered to be apoptotic. The Δψ m was assessed using the MitoProbe DilC 1 (1,1′, 3, 3, 3′, 3′ -hexamethylindodicarbo-cyanine iodide) assay kit for flow cytometry (Life Technologies, Eugene, OR, USA), following manufacturer's instructions. Neurons were incubated with the dye at 37 °C, for 30 min. Δψ m values were expressed as percentages, using carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (CCCP; 10 μM) for 15 min to define the 0% Δψ m value. In all cases, triplicates obtained from four different neuronal cultures were analysed on a FACScalibur flow cytometer (15 mW argon ion laser tuned at 488 nm;
CellQuest software, Becton Dickinson Biosciences) (Gomez-Sanchez et al., 2011) .
Quantitative reverse transcription-polymerase chain reaction (RT-qPCR) analysis
This was performed in total RNA samples, purified from neurons using a commercially available kit (Sigma), using the Power SYBER Green RNA-to-CT TM 1-Step Kit (Applied Biosystems, Township, USA). Reverse transcription was performed at 48ºC for 30 min, and PCR conditions were 10 min at 95ºC followed by 40 cycles of 15 s at 95ºC and 1 min at 60ºC, using the following forward and reverse primers (0.3 µM), respectively (Thermo Scientific):
5'-CAGCAGCGCGTCCACAGAG-3'and 5'-TCCTGATCCAGGCAATCAC-3' (p53 Mmu); 5'-CGAGAACGGTGGAACTTTGAC-3' and 5'-CAGGGCTCAGGTAGACCTTG-3' (p21, Mmu); 5'-AGCCCAGCAGCACTTAGAGT-3' and 5'-ACTCCTCCTCCTCCACACGCA-3' (PUMA, Mmu); 5´-TCAGCAATGCCTCCTGCACCA-3´ and 5´-GCATGGACTGTGGTCATGAG-3´ (GAPDH Mmu). The mRNA levels of each transcript were normalized to the GAPDH mRNA abundance obtained in the same sample. The relative mRNA levels were calculated using the ΔΔC t method and were expressed as the fold change between sample and calibrator.
Western blot analysis
Cells were lysed in RIPA buffer (2% sodium dodecylsulphate, 2 mM EDTA, 2 mM EGTA and 50 mM Tris pH 7.5) supplemented with phosphatase inhibitors (1mM Na 3 VO 4 and 50 mM NaF) and protease inhibitors (100 µM phenylmethylsulfonyl fluoride, 50 µg/ml antipapain, 50 µg/ml pepstatin, 50 µg/ml amastatin, 50 µg/ml leupeptin, 50 µg/ml bestatin and 50 µg/ml soybean trypsin inhibitor), stored on ice for 30 min and boiled for 5 min. Protein anti-Bax (1:500; Sc-493, Santa Cruz Biotechnology, Heidelberg, Germany); anti-PUMA (1:1000; ab54288, Abcam, Cambridge, UK); and anti-GAPDH (1:40000; Ambion, Cambridge, UK) overnight at 4ºC. GAPDH was used as loading control. After incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG (Pierce, Thermo Scientific) or goat anti-mouse IgG (Bio-Rad), membranes were incubated with the enhanced chemiluminescence SuperSignal West Dura (Pierce) for 5 min or Immobilon Western Chemiluminiscent HRP Substrate (Merck Millipore; Darmstadt, Germany) for 1 min, before exposure to Kodak XAR-5 film for 1 to 5 min, and the autoradiograms were scanned (Veas-Pérez De Tudela et al., 2015) . above the basal (resting) fluorescence (previously normalized to the resting fluorescence) after the addition of stimuli.
Immunocytochemistry
Neurons grown on glass coverslips were fixed with 4% (w/v, in PBS) paraformaldehyde for 30 min and immunostained with rabbit anti-cleaved caspase-3 (1:300; Cell Signaling Technology), mouse anti-p53 (1:200; 2524, Cell Signaling Technology) and mouse anti-Map2 (1:500; Sigma). Immunolabeling was detected using IgG-Cy2 (1:500) or IgG-Cy3
(1:500) secondary antibodies (Jackson ImmunoResearch Inc.). Nuclei were stained with 6diamidino-2-phenylindole (DAPI, Sigma D9542). Coverslips were washed, mounted with SlowFace light antifade reagent (Invitrogen) and examined under an Olympus IX81 Spinning disk confocal microscope (Olympus®, Tokyo, Japan) (Veas-Pérez de Tudela et al., 2015) .
Experimental in vivo model of Amyloid-β toxicity by single Aβ 25-35 intracerebroventricular injection
Stereotaxic injections were performed as previously done (Rodríguez et al., 2016) . Twelveweek-old wt (p53 +/+ ) and p53-KO (p53 -/-) male mice were anesthetized by inhalatory induction (4%) and maintained (2.5%) with sevofluorane (Sevorane; Abbot) in a gas mixture of 70% N 2 O, 30% O 2 , using a gas distribution column (Hersill H-3, Madrid, Spain) and a vaporizer (InterMed Penlons Sigma Delta, OX, UK). Mice were placed in a stereotaxic alignment system (Model 1900, David Kopf Instruments, CA, USA) with digital read out (Wizard 550, Anilam, NY, USA) and complemented with a stereomicroscope (Nikon SMZ 645, Tokyo, Japan) and a fiber optic cold light source (Schott KL1500 compact, Mainz, Germany). Injection was performed into the right ventricle at coordinates: 0.22 mm posterior to bregma, 1 mm lateral to midline, and 2.5 mm ventral to dura, using a 5-µl Hamilton syringe (Microliter 65RN, Hamilton, NV, USA) with a 26 S needle (type 2 tip). Either 4 μL of saline or oligomerized Aβ 25-35 (9 nmol) were injected using a 5-µL Hamilton syringe with a minipump (UltraMicroPump III, World Precision Instruments, USA) and a digital controller (Micro4 UMC4; World Precision Instruments, USA), at a rate of 0.8 µl/min during 5 min.
The syringe was left in place for 10 min before slowly retracting it to allow for Aβ infusion and to prevent reflux. Wounds were sutured, and animals were allowed to recover from anaesthesia in cages placed on a 37ºC thermostatted plate (Plactronic Digital, 25x60, JP Selecta, Barcelona, Spain). When indicated, animals were intraperitoneally treated with the p53 transactivation inhibitor, Pifithrin α (20 mg/kg; PFTα Sigma), immediately before Aβ injection.
Immunohistochemistry
Animals were deeply anesthetized by intraperitoneal injection of a mixture (1:4) of xylazine hydrochloride (Rompun; Bayer) and ketamine hydrochloride/chlorbutol (Imalgene; Merial) using 1 mL of the mixture per kg of body weight, and then perfused intraaortically with 0.9% NaCl followed by 5 mL/g body weight of Somogy's fixative [4% (wt/vol) paraformaldehyde, 0.2% (wt/vol) picric acid in 0.1 M phosphate buffer, pH 7.4]. After perfusion, brains were dissected out sagittally in two parts and postfixed, using Somogy's fixative, for 2 hours at room temperature. Brain blocks were then rinsed successively for 10 min, 30 min, and 2 h with 0.1 M phosphate buffer solution (PBS; pH 7.4) and sequentially immersed in 10, 20, and 30% (wt/vol) sucrose in PBS until they sank. After cryoprotection, 10, 20 and 40-µm-thick sagittal sections were obtained with a freezing-sliding cryostate (Leica; CM1950 AgProtect).
The 10 and 20-µm sections were placed on microscope slides, whereas the 40-µm slices were collected in 0.05% sodium azide (wt/vol) in 0.1 M PBS. Sections were rinsed in 0.1 M PBS three times each for 10 min and then incubated in: i) 1:1000 anti-NeuN (A-60; Merck Millipore), 1:500 anti-Map2 (AP-20; Sigma-Aldrich) or 1:200 anti-p53 (2524, Cell Signaling Technology) in 0.2% Triton X-100 (Sigma-Aldrich) and 5% goat serum (Jackson ImmunoResearch) in 0.1 M PBS for 72 h at 4 °C; ii) fluorophore-conjugated secondary antibodies (Jackson ImmunoResearch) in 0.05% Triton X-100 and 2% goat serum in 0.1 M PBS for 2 h at room temperature; and iii) 0.5 µg/mL DAPI in PBS for 10 min at room temperature (Bobo-Jiménez et al., 2017) . After rinsing with PBS, sections were mounted with Fluoromount (Sigma) aqueous mounting medium.
Confocal images were taken with a scanning laser confocal microscope ("Spinning Disk"
Roper Scientific Olympus IX81) with three lasers 405, 491 y 561 nm and equipped with 63× PL Apo oil-immersion objective for high resolution imaging and device digital camera (Evolve; Photometrics, Tucson, USA).
The dendrite integrity in the cortex and hippocampus was assayed by analyzing the density of Map2-positive dendrites in three sections per animal. Fluorescence 8-bit images were acquired as z stacks and were exported into ImageJ in tiff format for processing. Images were converted to grayscale 8-bit images and brightness/contrast was adjusted using the ImageJ "auto" function. All Map2-positive dendrites were automatically delineated using the "auto setting threshold" (default method) and "dark background" functions of ImageJ. Thresholded images were subsequently quantified as percent area (area fraction) using the "analyzemeasure" function, which represents the percentage of pixels in the image that have been highlighted (% area) (Bobo-Jiménez et al., 2017) . Values are mean ± SEM from 15 measurements.
Terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay
TUNEL assay was performed in 20 µm brain sections, following the manufacturer's protocol (Roche Diagnostics, Heidelberg, Germany). Brain sections, fixed as above, were preincubated in TUNEL buffer containing 1 mM CoCl 2 , 140 mM sodium cacodylate and 0.3% Triton X-100 in 30 mM Tris buffer, pH 7.2, for 30 min. After incubation at 37 °C with the TUNEL reaction mixture containing terminal deoxynucleotidyl transferase (800 U/ml) and nucleotide mixture (1 μM) for 90 min, sections were rinsed with PBS and counterstained with Cy3streptavidin (Jackson Immunoresearch Laboratories) (Rodríguez et al., 2016) .
Statistical analysis
Results are expressed as mean ± S.E.M. A one-way ANOVA with a least significant difference post hoc test was used to compare values between multiple groups, and a twotailed, unpaired Student's t-test was used for two-group comparisons. In all cases, p<0.05 were considered significant. Statistical analyses were performed using SPSS Statistics 24.0 for Macintosh (IBM). 
Figure legends
